Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

被引：3
|
作者：
Yi, J.
Thongprasert, S.
Doval, D.
Lee, J.
Cho, M. N.
Park, S. H.
Park, J. O.
Park, Y. S.
Kang, W. K.
Lim, H. Y.
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Chiang Mai Univ, Chiang Mai 50000, Thailand
[3] Rajiv Gandhi Canc Inst, New Delhi, India
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Canc, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14653
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
    Yi, Jun Ho
    Thongprasert, Sumitra
    Lee, Jeeyun
    Doval, D. C.
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 196 - 201
  • [2] Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Yung-Jue Bang
    Yoon-Koo Kang
    Won K. Kang
    Narikazu Boku
    Hyun C. Chung
    Jen-Shi Chen
    Toshihiko Doi
    Yan Sun
    Lin Shen
    Shukui Qin
    Wai-Tong Ng
    Jennifer M. Tursi
    Maria J. Lechuga
    Dongrui Ray Lu
    Ana Ruiz-Garcia
    Alberto Sobrero
    Investigational New Drugs, 2011, 29 : 1449 - 1458
  • [3] Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Kang, Won K.
    Boku, Narikazu
    Chung, Hyun C.
    Chen, Jen-Shi
    Doi, Toshihiko
    Sun, Yan
    Shen, Lin
    Qin, Shukui
    Ng, Wai-Tong
    Tursi, Jennifer M.
    Lechuga, Maria J.
    Lu, Dongrui Ray
    Ruiz-Garcia, Ana
    Sobrero, Alberto
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1449 - 1458
  • [4] Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study
    Roth, Annekathrin
    Schleyer, Eberhard
    Schoppmeyer, Konrad
    Kluge, Regine
    Wittekind, Christian
    Moessner, Joachim
    Wiedmann, Marcus
    ONKOLOGIE, 2011, 34 (8-9): : 469 - 470
  • [5] A phase II study of anlotinib with cediranib as a second-line treatment for patients with advanced biliary tract cancers (aBTCs).
    Zhao, Ruihua
    Zong, Hong
    Jin, Shuiling
    Zhong, Qian
    Jiang, Miao
    Jin, Ming
    Li, Rui
    Jiang, Guozhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study
    Lee, Yong-Pyo
    Oh, Sung Yong
    Kim, Kwang Min
    Go, Se-Il
    Kim, Jung Hoon
    Huh, Seok Jae
    Kang, Jung Hun
    Ji, Jun Ho
    CANCERS, 2022, 14 (08)
  • [7] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
    Zong Hong
    Zhong Qian
    Zhao Ruihua
    Jin Shuiling
    Zhou Chuang
    Zhang Xiaojian
    Shi Jianxiang
    Qiao Shishi
    Han Jinming
    Jiang Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer
    Yoon, J. S.
    Lee, K-H.
    Cheon, G. J.
    Bang, Y-J.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Bang, Y.
    Kang, Y.
    Kang, W.
    Boku, N.
    Chung, H.
    Tursi, J.
    Lechuga, M. J.
    Verkh, L.
    Chao, R.
    Sobrero, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 272 - 272
  • [10] Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study
    Bang, Y.
    Kang, Y.
    Kang, W.
    Boku, N.
    Chung, H.
    Lanzalone, S.
    Lechuga, M. J.
    Sherman, L.
    Chao, R.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345